Pharmaceutical

Chinese NMPA approves Innovent and IASO Bio’s myeloma therapy

China has granted approval for Innovent Biologics and IASO Bio Fucaso for treating relapsed or refractory multiple myeloma (RRMM) in adults.

Jul 3, 2023 - 20:00
Chinese NMPA approves Innovent and IASO Bio’s myeloma therapy
China has granted approval for Innovent Biologics and IASO Bio Fucaso for treating relapsed or refractory multiple myeloma (RRMM) in adults.
Read the original article

Tags:

Previous Article

Eli Lilly’s retatrutide sets new record for weight loss in obesity space

Next Article

Madrigal seeks expedited approval for NASH treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Zydus Lifesciences gets grant for oral suspension of mycophenolate mofetil

Zydus Lifesciences gets grant for oral suspension of my...

Jun 8, 2024

Cidara to continue its CD388 influenza programme despite Janssen’s contrary decision

Cidara to continue its CD388 influenza programme despit...

Jul 21, 2023

Self-amplifying RNA and vaccine innovation: getting from concept to clinic

Self-amplifying RNA and vaccine innovation: getting fro...

May 29, 2024